HBV News and Research

RSS

Online platforms can increase drug overdose

HSE University researchers together with specialists from the Humanitarian Action Charitable Fund (St. Petersburg) and the University of Michigan School of Public Health (USA) studied the specifics of remote work with Russian people who use drugs to reduce the harm of drug use.

16 Mar 2021

Princeton researchers elucidate how hepatitis B virus establishes chronic infection

Researchers at Princeton have determined how five cellular proteins contribute to an essential step in the life cycle of hepatitis B virus (HBV).

11 Mar 2021

Novel gel electrophoresis method for MS-based quantification of protein biomarkers

Mass spectrometry (MS) is a powerful method for biomarker analysis because it enables highly sensitive and accurate measurement of target molecules in clinical samples.

18 Feb 2021

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

New combination therapy proven to be highly effective in HBV infection model

Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer.

4 Feb 2021

Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma

Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: Intrahepatic Cholangiocarcinoma (ICC), Perihilar Cholangiocarcinoma (PCC), and Distal Extrahepatic Tumors (DET).

3 Feb 2021

Reduced expression of TBX15 in tumor tissue represents a prognostic biomarker for HCC patients

The cover for issue 52 of Oncotarget features Figure 1, "Volcano plots of DNA methylation in tumor tissues compared with nontumor tissue," published in "Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma" by Morine, et al. which reported that the authors conducted a genome-wide analysis of DNA methylation of the tumor and non-tumor tissue of 15 patients with Hepatocellular carcinoma (HCC), and revealed TBX15 was the most hypermethylated gene of the tumor.

25 Jan 2021

Trial results support efficacy of incentivizing vaccine adherence

As the United States struggles to control record-breaking increases in COVID-19 infections and hospitalizations, the roll-out of two approved vaccines offers tremendous hope for saving lives and curbing the pandemic.

22 Jan 2021

COVID-19 has transformed the world of vaccines

Researchers at GlaxoSmithKline (GSK) in Italy and Belgium say the coronavirus disease 2019 (COVID-19) pandemic is transforming the world of vaccinology by accelerating vaccine development and the availability of powerful technologies.

20 Jan 2021

Researchers design armored immune cells to attack recurring cancer in liver transplant patients

Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant drugs patients take to avoid organ rejection.

19 Jan 2021

Study suggests 5’UTR of SARS-CoV-2 might be of pangolin coronavirus origin

Findings from a new genomic sequencing study support the hypothesis that the pangolin was the intermediate host for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that enabled transmission of the virus to humans.

26 Oct 2020

Study highlights need for culturally relevant programs to educate Black communities on hepatitis B

Hepatitis B disproportionately impacts U.S. Blacks, including African American and Haitian Blacks. Both communities suffer from widespread misinformation and access to care issues that might avert disease detection and prevention, according to a study published in Cancer Causes & Control by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Oct 2020

BM32 vaccine against grass pollen allergy could be potential treatment for hepatitis B infection

Chronic hepatitis B infections represent a global health problem that could hitherto only be treated by chemotherapy.

26 Aug 2020

De novo designed SARS-CoV-2 nanoparticle vaccine

In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.

14 Aug 2020

Natural controllers shed light on immunity mechanisms against hepatitis B

Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.

13 Aug 2020

European Commission approves first drug for hepatitis D

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.

5 Aug 2020

ECDC and WHO collaborate to track the status of hepatitis infections across EU

Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed.

28 Jul 2020

Study estimates the past and present burden of viral hepatitis through blood transfusions

What is the incidence of viral hepatitis caused by blood transfusions before and after Sweden introduced screening of blood in the early 1990s? In an article published in Eurosurveillance ahead of World Hepatitis Day on 28 July, the authors also try to estimate how many people of those who were infected with hepatitis B and C through blood transfusion still live with undiagnosed hepatitis.

23 Jul 2020

Effect of human genes on severity and infectivity of SARS-CoV-2

Now, a new paper published on the preprint server medRxiv* reports the results of an analysis of the association between the genetic variants in the patients and the clinical progression of the disease. The study included 332 patients hospitalized with COVID-19 in a single-center, with widely varying laboratory and clinical features. There were 25, 12, and 17 patients with asymptomatic, mild, and critical disease.

14 Jun 2020

Immune cell discovery could help develop new treatments for hepatitis B

For the first time, researchers at The Westmead Institute for Medical Research have identified and described a new and unique subset of human cells that are involved in the immune response against hepatitis B (HBV) infection. The discovery could help develop new treatments for HBV and inform future vaccine design.

9 Jun 2020